skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.08d (Release date: 2017-08-28)
SearchBox Top
SearchBox Bottom
Tigatuzumab (Code C62482)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Tigatuzumab

Definition: A humanized agonistic monoclonal antibody directed against human tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) with potential antitumor activity. Mimicking the natural receptor ligand TRAIL, tigatuzumab binds to TRAIL-R2, activating signal transduction pathways that may result in tumor cell apoptosis and a reduction in tumor growth. A member of the tumor necrosis factor (TNF) receptor family, TRAIL-R2, also known as DR5 (death receptor 5), is expressed on the surfaces of many types of malignant cells.

Display Name: Tigatuzumab

Label: Tigatuzumab

NCI Thesaurus Code: C62482 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2973415  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
anti-[Homo sapiens TNFRSF10B (Tumor Necrosis Factor Receptor Superfamily Member 10B, DR5, TRAIL-R2, CD262)] Humanized Monoclonal TRA-8
Anti-DR5 MoAb
Anti-TRAIL-R2 MoAb

External Source Codes: 
PDQ Closed Trial Search ID 489323
PDQ Open Trial Search ID 489323 (check for NCI PDQ open clinical trial info)
UMLS CUI C2973415

Other Properties:
     Name Value (qualifiers indented underneath)
code C62482
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name CS-1008
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Immunologic Factor

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom